Introduction: High patient compliance, noninvasiveness, and self-administration are the leading features of vaccine delivery through the oral route. The implementation of swift mass vaccination campaigns in pandemic outbreaks fascinates the use of oral vaccination. This approach can elicit both mucosal and systemic immune responses to protect against infection at the surface of the mucosa.
Area Covered: As pathogen entry and spread mainly occurs through the gastrointestinal tract (GIT) mucosal surfaces, oral vaccination may protect and limit disease spread. Oral vaccines target various potential mucosal inductive sites in the GIT, such as the oral cavity, gastric area, and small intestine. Orally delivered vaccines having subunit and nucleic acid pass through various GIT-associated risks, such as the biodegradation of biologics and their reduced absorption. This article presents a summarized review of the existing technologies and prospects for oral vaccination.
Expert Opinion: The intestinal mucosa focuses on current approaches, while future strategies target new mucosal sites, i.e. oral cavity and stomach. Recent developments in biologic delivery through the oral route and their potential use in future oral vaccination are mainly considered.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14760584.2021.1990044 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The therapeutic armamentarium that has been made available from the beginning of the emergency phase of the COVID-19 pandemic to date is briefly reviewed, and an overview of the real-world clinical evidence published by the Italian medical and scientific community during the last three years is presented herein. Prior to the introduction of a vaccine for SARS-CoV-2, several treatment options were implemented from the onset given the evidence that a "cytokine storm" was present during infection with SARS-CoV-2. However, with the exception of tocilizumab, baricitinib and perhaps anakinra, most studies with anti-cytokine biological agents in patients with severe COVID-19 did not show any significant clinical improvement or decrease in mortality at day 28.
View Article and Find Full Text PDF[Acute flaccid paralysis surveillance in Niger from 1998 to 2021].
Med Trop Sante Int
December 2024
Département de médecine et spécialités médicales, Université Abdou Moumouni, FSS, Hôpital général de référence, BP 10896, Niamey, Niger.
Introduction: Acute flaccid paralysis (AFP) caused by acute anterior poliomyelitis (AAP) remains endemic in some Asian and African countries, particularly Niger. Performance indicators defined by the WHO are used to evaluate the AFP surveillance system in affected countries. The objective of this study is to assess its outcomes in Niger from 1998 to 2021.
View Article and Find Full Text PDFLeveraging near-real-time patient and population data to incorporate fluctuating risk of severe COVID-19: development and prospective validation of a personalised risk prediction tool.
EClinicalMedicine
March 2025
VA Boston Cooperative Studies Program, Boston, MA, USA.
Background: Novel strategies that account for population-level changes in dominant variants, immunity, testing practices and changes in individual risk profiles are needed to identify patients who remain at high risk of severe COVID-19. The aim of this study was to develop and prospectively validate a tool to predict absolute risk of severe COVID-19 incorporating dynamic parameters at the patient and population levels that could be used to inform clinical care.
Methods: A retrospective cohort of vaccinated US Veterans with SARS-CoV-2 from July 1, 2021, through August 25, 2023 was created.
Precision therapeutic targets for HPV-positive cancers: an overview and new insights.
Infect Agent Cancer
March 2025
State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases & Frontier Innovation Center for Dental Medicine Plus & Research Unit of Oral Carcinogenesis and Management & Chinese Academy of Medical Sciences, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, Sichuan, China.
The increasing incidence and mortality rates of HPV-positive cancers, particularly HPV-positive head and neck cancer, in recent years have emphasized the pressing need for more efficacious treatment options. Recent studies have elucidated the molecular distinctions between HPV-positive and HPV-negative cancers, which are crucial for developing precise and effective therapeutic strategies. This review updates the most recent findings on the molecular variances between HPV-positive and HPV-negative cancers, evaluates current treatments for HPV-positive cancers, and summarizes emerging frontiers in HPV-targeted therapies aimed at developing more effective and precise interventions against these cancers.
View Article and Find Full Text PDFDrug-associated gingival disorders: a retrospective pharmacovigilance assessment using disproportionality analysis.
BDJ Open
March 2025
Bahrain Defence Force Royal Medical Services, Riffa, Kingdom of Bahrain.
Background: Drug-associated gingival disorders can negatively impact on oral health. This study aimed to utilize the United States Food and Drug Administration Adverse Event Reporting System (USFDA AERS) to comprehensively assess the associations between medications and specific gingival disorders.
Methods: Data were extracted from the USFDA AERS from 2004-2024 using Preferred Terms for eight gingival disorders.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!